For how we live.
In TRIUMPH-1, a triple hormone-receptor agonist produced a 25% average weight loss at the top dose over 80 weeks, and also eased knee pain and sleep apnoea. The trial was funded by Eli Lilly.
An updated Annals review now covers 38 randomised trials and 25,816 people. Tirzepatide leads the marketed drugs at 19.0% placebo-subtracted weight loss; the experimental multiagonists run higher.
Orforglipron removes the injection from weight-loss medicine — a real change for people who refused one. Supply, cost, and coverage are the harder problems it does not solve.
Tirzepatide topped weight loss at 14.9%. But only subcutaneous semaglutide showed a mortality benefit — and no drug moved the needle on quality of life or kidney failure.
In TRANSCEND-T2D-1, the triple-hormone agonist cut HbA1c up to 1.12 points beyond placebo over 40 weeks and trimmed bodyweight 15.3% at the top dose in early type 2 diabetes.
TRIUMPH-4 tested retatrutide in 445 adults with obesity and knee osteoarthritis. The weight numbers are striking. So are the discontinuation numbers sitting beside them.